PACT Biomaterials valuation, funding and investors
PACT Biomaterials works in sustainable biomaterials manufacturing, based in Cambridge, United Kingdom. Founded in 2020, it has about 49 employees.
- Last round
- Series A · $20.0M · Oct 2025
- Valuation at last round
- $115M · implied
- Headcount
- 49 · up
- Grade
- C
- Founded
- 2020
PACT Biomaterials valuation today
VCMC values PACT Biomaterials at $209M today, with a range of $82.7M to $300M and a grade of C. The valuation starts from its last funding round, a Series A round in Oct 2025.
Valuation by date (85 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2020 | $10.2M | $3.72M – $28.1M | $11.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2020 | $10.3M | $3.75M – $28.3M | $11.5M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2020 | $10.4M | $3.78M – $28.6M | $11.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2020 | $10.5M | $3.82M – $28.8M | $11.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2020 | $10.6M | $3.85M – $29.1M | $11.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2020 | $10.7M | $3.89M – $29.3M | $11.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jul 2020 | $10.8M | $3.92M – $29.6M | $12.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Aug 2020 | $10.9M | $3.96M – $29.9M | $12.1M (+11%) | before first round | – | unknown | D | 0% |
| 1 Sep 2020 | $11.0M | $3.99M – $30.1M | $12.2M (+11%) | before first round | – | unknown | D | 0% |
| 1 Oct 2020 | $11.1M | $4.03M – $30.4M | $12.3M (+11%) | before first round | – | unknown | D | 0% |
| 1 Nov 2020 | $11.2M | $4.07M – $30.7M | $12.4M (+11%) | before first round | – | unknown | D | 0% |
| 1 Dec 2020 | $11.3M | $4.10M – $31.0M | $12.6M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jan 2021 | $11.4M | $4.14M – $31.2M | $12.7M (+11%) | before first round | – | unknown | D | 0% |
| 1 Feb 2021 | $11.5M | $4.18M – $31.5M | $12.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Mar 2021 | $11.6M | $4.21M – $31.8M | $12.8M (+11%) | before first round | – | unknown | D | 0% |
| 1 Apr 2021 | $11.7M | $4.25M – $32.1M | $12.9M (+11%) | before first round | – | unknown | D | 0% |
| 1 May 2021 | $11.8M | $4.29M – $32.4M | $13.0M (+11%) | before first round | – | unknown | D | 0% |
| 1 Jun 2021 | $11.9M | $4.33M – $32.7M | $13.1M (+10%) | before first round | – | unknown | D | 0% |
| 1 Jul 2021 | $12.0M | $4.37M – $33.0M | $13.2M (+10%) | before first round | – | unknown | D | 0% |
| 1 Aug 2021 | $12.1M | $4.41M – $33.3M | $13.3M (+10%) | before first round | – | unknown | D | 0% |
| 1 Sep 2021 | $12.2M | $4.45M – $33.6M | $13.4M (+10%) | before first round | – | unknown | D | 0% |
| 1 Oct 2021 | $12.3M | $4.49M – $33.9M | $13.5M (+10%) | before first round | – | unknown | D | 0% |
| 1 Nov 2021 | $12.4M | $4.53M – $34.2M | $13.6M (+10%) | before first round | – | unknown | D | 0% |
| 1 Dec 2021 | $12.5M | $4.57M – $34.5M | $13.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2022 | $12.7M | $4.61M – $34.8M | $13.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2022 | $12.8M | $4.65M – $35.1M | $13.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2022 | $12.8M | $4.68M – $35.3M | $14.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2022 | $12.9M | $4.71M – $35.6M | $14.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2022 | $13.0M | $4.75M – $35.8M | $14.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2022 | $13.1M | $4.78M – $36.1M | $14.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2022 | $13.2M | $4.82M – $36.3M | $14.5M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2022 | $13.3M | $4.85M – $36.6M | $14.6M (+9%) | before first round | – | unknown | D | 0% |
| 1 Sep 2022 | $13.4M | $4.89M – $36.9M | $14.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Oct 2022 | $13.5M | $4.92M – $37.2M | $14.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Nov 2022 | $13.6M | $4.96M – $37.4M | $14.9M (+9%) | before first round | – | unknown | D | 0% |
| 1 Dec 2022 | $13.7M | $5.00M – $37.7M | $15.0M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jan 2023 | $13.8M | $5.04M – $38.0M | $15.1M (+9%) | before first round | – | unknown | D | 0% |
| 1 Feb 2023 | $13.9M | $5.07M – $38.3M | $15.2M (+9%) | before first round | – | unknown | D | 0% |
| 1 Mar 2023 | $14.0M | $5.11M – $38.5M | $15.3M (+9%) | before first round | – | unknown | D | 0% |
| 1 Apr 2023 | $14.1M | $5.15M – $38.8M | $15.4M (+9%) | before first round | – | unknown | D | 0% |
| 1 May 2023 | $14.2M | $5.18M – $39.1M | $15.6M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jun 2023 | $14.3M | $5.22M – $39.4M | $15.7M (+9%) | before first round | – | unknown | D | 0% |
| 1 Jul 2023 | $14.5M | $5.26M – $39.7M | $15.8M (+9%) | before first round | – | unknown | D | 0% |
| 1 Aug 2023 | $14.6M | $5.30M – $40.0M | $15.8M (+8%) | before first round | – | unknown | D | 0% |
| 1 Sep 2023 | $14.7M | $5.34M – $40.3M | $15.8M (+8%) | before first round | – | unknown | D | 0% |
| 1 Oct 2023 | $14.8M | $5.38M – $40.6M | $15.8M (+7%) | before first round | – | unknown | D | 0% |
| 1 Nov 2023 | $14.9M | $5.42M – $40.9M | $15.8M (+6%) | before first round | – | unknown | D | 0% |
| 1 Dec 2023 | $15.0M | $5.46M – $41.2M | $15.8M (+5%) | before first round | – | unknown | D | 0% |
| 1 Jan 2024 | $15.1M | $5.50M – $41.5M | $15.8M (+5%) | before first round | – | unknown | D | 0% |
| 1 Feb 2024 | $15.2M | $5.54M – $41.8M | $15.8M (+4%) | before first round | – | unknown | D | 0% |
| 1 Mar 2024 | $16.6M | $6.03M – $45.5M | $17.1M (+3%) | before first round | 26 | unknown | D | 0% |
| 1 Apr 2024 | $16.7M | $6.08M – $45.9M | $17.1M (+2%) | before first round | 26 | unknown | D | 0% |
| 1 May 2024 | $16.8M | $6.12M – $46.2M | $17.1M (+1%) | before first round | 26 | unknown | D | 0% |
| 1 Jun 2024 | $16.9M | $6.17M – $46.5M | $17.1M (+1%) | before first round | 26 | unknown | D | 0% |
| 1 Jul 2024 | $17.1M | $6.21M – $46.9M | $17.1M (0%) | before first round | 26 | unknown | D | 0% |
| 1 Aug 2024 | $21.5M | $7.08M – $48.2M | $21.5M (0%) | before first round | 31 | up | C | 0% |
| 1 Sep 2024 | $21.5M | $7.08M – $48.2M | $21.5M (0%) | before first round | 31 | up | C | 0% |
| 28 Sep 2024 | $72.9M | $47.8M – $222M | $146M (+100%) | after a round | 31 | up | C | 0% |
| 1 Oct 2024 | $73.3M | $47.8M – $222M | $146M (+98%) | after a round | 31 | up | C | 0% |
| 1 Nov 2024 | $77.8M | $47.8M – $222M | $146M (+87%) | after a round | 39 | growing | C | 0% |
| 1 Dec 2024 | $82.3M | $47.8M – $222M | $146M (+77%) | after a round | 39 | growing | C | 0% |
| 1 Jan 2025 | $87.3M | $47.8M – $222M | $146M (+67%) | after a round | 39 | growing | C | 0% |
| 1 Feb 2025 | $92.6M | $47.8M – $222M | $146M (+57%) | after a round | 39 | growing | C | 0% |
| 1 Mar 2025 | $97.7M | $47.8M – $222M | $146M (+49%) | after a round | 39 | growing | C | 0% |
| 1 Apr 2025 | $104M | $47.8M – $222M | $146M (+41%) | after a round | 39 | growing | C | 0% |
| 1 May 2025 | $110M | $47.8M – $222M | $146M (+33%) | after a round | 39 | growing | C | 0% |
| 1 Jun 2025 | $116M | $47.8M – $222M | $146M (+25%) | after a round | 39 | growing | C | 0% |
| 1 Jul 2025 | $123M | $47.8M – $222M | $146M (+18%) | after a round | 39 | growing | C | 0% |
| 1 Aug 2025 | $132M | $48.4M – $224M | $147M (+12%) | after a round | 41 | growing | C | 0% |
| 1 Sep 2025 | $140M | $48.4M – $224M | $147M (+5%) | after a round | 41 | growing | C | 0% |
| 1 Oct 2025 | $147M | $48.2M – $224M | $147M (0%) | after a round | 41 | up | C | 0% |
| 31 Oct 2025 | $115M | $80.7M – $293M | $206M (+80%) | after a round | 41 | up | C | 0% |
| 1 Nov 2025 | $115M | $80.7M – $293M | $206M (+79%) | after a round | 44 | growing | C | 0% |
| 1 Dec 2025 | $121M | $80.7M – $293M | $206M (+71%) | after a round | 44 | growing | C | 0% |
| 1 Jan 2026 | $127M | $80.7M – $293M | $206M (+63%) | after a round | 44 | growing | C | 0% |
| 1 Feb 2026 | $133M | $81.1M – $294M | $207M (+55%) | after a round | 45 | growing | C | 0% |
| 1 Mar 2026 | $140M | $81.1M – $294M | $207M (+48%) | after a round | 45 | up | C | 0% |
| 1 Apr 2026 | $147M | $81.1M – $294M | $207M (+41%) | after a round | 45 | up | C | 0% |
| 1 May 2026 | $156M | $82.7M – $300M | $211M (+36%) | after a round | 49 | up | C | 0% |
| 1 Jun 2026 | $164M | $82.7M – $300M | $211M (+29%) | after a round | 49 | up | C | 0% |
| 1 Jul 2026 | $172M | $82.7M – $300M | $211M (+23%) | after a round | 49 | up | C | 0% |
| 1 Aug 2026 | $182M | $82.7M – $300M | $211M (+16%) | after a round | 49 | up | C | 0% |
| 1 Sep 2026 | $191M | $82.7M – $300M | $211M (+10%) | after a round | 49 | up | C | 0% |
| 1 Oct 2026 | $201M | $82.7M – $300M | $211M (+5%) | after a round | 49 | up | C | 0% |
| 24 Oct 2026 | $209M | $82.7M – $300M | $211M (+1%) | after a round | 49 | up | C | 0% |
Key facts about PACT Biomaterials
- Founded
- 2020
- Headquarters
- Cambridge, United Kingdom
- Employees
- about 49 +11% in a year
- Total raised
- $32M
- Funding rounds
- 2
- Last round
- Series A Oct 2025
PACT Biomaterials was founded in 2020 by Niels Ramay and Yudi Ding.
PACT Biomaterials funding history
PACT Biomaterials has 2 funding rounds on record, from Sep 2024 to Oct 2025, $32M in total. None disclosed a valuation.
Series A 30 Oct 2025
Led by Forbion; with HV Capital, Hoxton Ventures, Polytechnique Ventures.
Sources: techfundingnews.com, startup.eu, twobirds.com
$20M
Seed 27 Sep 2024
Led by Hoxton Ventures; with ReGen Ventures, Celsius Industries, Polytechnique Ventures.
Sources: finsmes.com
$12M
PACT Biomaterials investors
6 investors have backed PACT Biomaterials; Hoxton Ventures and Forbion led at least one round.
- Hoxton Ventures lead, 2 rounds
- Celsius Industries
- HV Capital
- ReGen Ventures
What PACT Biomaterials does
PACT Biomaterials works in plastics products, with 15 recorded offerings and customers in luxury goods and consumer goods.
PACT Biomaterials is a British company engaged in the development and production of sustainable biomaterials for use in luxury goods and other industries. The company focuses on creating biomaterials that are environmentally friendly and designed to reduce environmental impact. PACT Biomaterials also operates as a research and development entity, working with scientists, engineers, and creatives to advance sustainable product design and manufacturing.
Description from Veridion's company data.
Products and services
- Sustainable Biomaterials Manufacturing
- Biomaterials Product Innovation
- Customizable Biomaterials Development
- Eco-Friendly Material Engineering
- Luxury Goods Material Supply
- Sustainable Product Design Consulting
- Collagen-Based Material Engineering
- Natural Ingredient Biomaterial Development
- Flexible Material Solutions
- Handfeel Material Solutions
- Customizable Material Solutions
- Environmentally Friendly Material Supply
- Sustainable Material Distribution
- Biomaterials Sustainability Consulting
- Biomaterials Application Research and Development
Markets
- Luxury Goods
- Consumer Goods
Technology
- Collagen-Based Biomaterials
Business model
- Business-to-Business
- Manufacturing
Industry codes (NAICS)
- 325998 All Other Miscellaneous Chemical Product and Preparation Manufacturing 100% match
Questions about PACT Biomaterials
What is PACT Biomaterials worth?
Valuation $209M (range $82.7M to $300M), as of 24 Oct 2026.
Has PACT Biomaterials raised money?
PACT Biomaterials has 2 funding rounds on record, from Sep 2024 to Oct 2025, $32M in total. None disclosed a valuation.
Who has invested in PACT Biomaterials?
Hoxton Ventures, Forbion, Polytechnique Ventures, Celsius Industries, HV Capital and ReGen Ventures. Lead investors include Hoxton Ventures and Forbion.
How many people work at PACT Biomaterials?
About 49, up 11% over the last year. Headcount grew from 26 in Mar 2024 to 49 in Sep 2026.
What does PACT Biomaterials do?
PACT Biomaterials works in plastics products, with 15 recorded offerings and customers in luxury goods and consumer goods. Its main offerings are sustainable biomaterials manufacturing, biomaterials product innovation and customizable biomaterials development.
When was PACT Biomaterials founded, and where is it based?
PACT Biomaterials was founded in 2020 and is based in Cambridge, United Kingdom. It has about 49 employees, up 11% over the last year.